Simurosertib

N/A

Report date: 2025/08/24 20:00:07
NME

Base Information

Drug NameSimurosertib
Drug Alias NameCell division cycle 7 inhibitor TAK-931Simurosertib - Takeda OncologyTAK-931ZL-2309
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell division cycle 7-related protein kinase inhibitors
TargetsCell division cycle 7-related protein kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsMainland China +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZai Lab (Shanghai) Co LtdMillennium Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A